FDF | Finished Dosage Formulation


New in 2018: FDF Japan Zone

FDF is the latest zone added to CPhI Japan, bringing together every aspect of the finished dosage supply chain, from Big Pharma and CMO to in/out-licensing and dossier specialists. FDF explores key market facts and gives attendees and exhibitors a platform to connect with ideal partners on a successful route to market.



Why FDF Japan?

  • Japan is now on the way to the full-fledged aging society
  • National Medical Expenditure in FY2025 is estimated to become 61 trillion JPY(¥)
  • Budget constraints and cost-push pressure of the aging population lead the Government to take various actions including promotion of generics a national policy
  • Strong governmental support, increased levels of drug maker activities and the shifting attitudes of consumers will contribute to the rapid growth of generic drugs in Japan
  • Generic drug sales is forecast to reach a value of USD17.1 billion by 2021 and USD21.9 billion by 2026. This represents a 10-year CAGR of 4.7% in US dollar terms. It is expected that generic medicines will increase their share of the total from around 13% in 2016 to just over 20% by 2026.